RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
RenovoRx, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.16+0.02 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $54.87M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
20.4%
9M of 45M shares
Institutional holders
28
3 new, 6 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
13 buys · 0 sales
Net bought $84.49K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| AIGH Capital Management LLC | 4,430,493 | 9.80% | 13G (passive) amendment | Mar 31, 2026 |
| AIGH Capital Management, LLC | 3,467,275 | 9.50% | 13G (passive) | Mar 31, 2025 |
| Orin Hirschman | 2,615,193 | 7.10% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNXT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 4,405,439 | 9.76% | $4.32M | +699,242 | 0.27% |
| Bleichroeder LP | 1,666,098 | 3.69% | $1.63M | – | 0.29% |
| Vanguard Capital Management LLC | 1,443,742 | 3.20% | $1.41M | −3,435 | 0.00% |
| Geode Capital Management, LLC | 424,148 | 0.94% | $415.69K | +42,425 | 0.00% |
| Wealthspire Advisors, LLC | 252,525 | 0.56% | $247.48K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 240,330 | 0.53% | $235.52K | +82,428 | 0.00% |
| Citadel Advisors LLC | 133,597 | 0.30% | $130.93K | −99,087 | 0.00% |
| Chicago Partners Investment Group LLC | 92,356 | 0.20% | $78.92K | – | 0.00% |
| Northern Trust Corp | 85,207 | 0.19% | $83.50K | +43,046 | 0.00% |
| Northwestern Mutual Wealth Management Co | 74,596 | 0.17% | $73.10K | −24,864 | 0.00% |
| Caprock Group, LLC | 63,940 | 0.14% | $62.66K | – | 0.00% |
| Jane Street Group, LLC | 46,399 | 0.10% | $45.47K | +22,262 | 0.00% |
| Kestra Advisory Services, LLC | 35,520 | 0.08% | $34.81K | – | 0.00% |
| Two Sigma Securities, LLC | 34,788 | 0.08% | $34.09K | +16,892 | 0.00% |
| XTX Topco Ltd | 29,983 | 0.07% | $29.38K | −528 | 0.00% |
| Clear Creek Financial Management, LLC | 29,058 | 0.06% | $28.48K | New | 0.00% |
| State Street Corp | 26,152 | 0.06% | $25.63K | – | 0.00% |
| UBS Group AG | 20,820 | 0.05% | $20.40K | +17,482 | 0.00% |
| HighTower Advisors, LLC | 20,000 | 0.04% | $19.60K | – | 0.00% |
| Cetera Investment Advisers | 19,000 | 0.04% | $18.62K | +1,000 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 9M | 20.4% | 3 / 8 | 6 / 6 | 1M | 0M |
| Q1 2026 | 31 | 9M | 19.0% | 4 / 11 | 4 / 5 | 4M | 0M |
| Q4 2025 | 33 | 7M | 14.6% | 8 / 8 | 7 / 6 | 1M | 1M |
| Q3 2025 | 31 | 7M | 15.8% | 8 / 5 | 6 / 2 | 0M | 2M |
| Q2 2025 | 25 | 9M | 19.5% | 5 / 4 | 4 / 7 | 1M | 2M |
| Q1 2025 | 27 | 10M | 22.3% | 13 / 7 | 2 / 4 | 9M | 0M |
| Q4 2024 | 18 | 1M | 2.2% | 6 / 3 | 3 / 1 | 0M | 1M |
| Q3 2024 | 13 | 2M | 4.2% | 2 / 3 | 3 / 5 | 1M | 0M |
| Q2 2024 | 17 | 1M | 2.0% | 8 / 4 | 1 / 1 | 1M | 0M |
| Q1 2024 | 10 | 0M | 0.7% | 0 / 5 | 1 / 2 | 0M | 0M |
| Q4 2023 | 12 | 0M | 0.7% | 4 / 3 | 1 / 6 | 0M | 0M |
| Q3 2023 | 14 | 0M | 0.8% | 5 / 3 | 2 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RNXT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,034,193 | 2.29% | $1.01M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 379,921 | 0.84% | $372.32K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 178,391 | 0.40% | $162.23K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 77,982 | 0.17% | $70.92K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 49,555 | 0.11% | $45.07K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 29,628 | 0.07% | $29.04K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 20,477 | 0.05% | $18.62K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ramtin Agah | Chief Medical Officer, Director | 1,773,460 | 3.93% | Apr 7, 2026 |
| Shaun Bagai | Chief Executive Officer, Director | 364,340 | 0.81% | Apr 7, 2026 |
| Mark Voll | Chief Financial Officer | 319,580 | 0.71% | Sep 15, 2026 |
| Leesa Gentry | Chief Clinical Officer | – | – | Apr 7, 2026 |
| Ron Kocak | VP, Controller and PAO | 12,595 | 0.03% | Jul 3, 2025 |
| Una S. Ryan | Director | 80,959 | 0.18% | Jun 24, 2026 |
| Laurence Marton | Director | 75,884 | 0.17% | Mar 24, 2026 |
| K. Angela Macfarlane | Director | 40,983 | 0.09% | Oct 2, 2025 |
| Robert J. Spiegel | Director | 40,983 | 0.09% | Oct 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Voll Chief Financial Officer | Sep 10, 2026 | Award | +80,000 | – | – | 222,380 |
| Mark Voll Chief Financial Officer | May 19, 2026 | Buy | +25,000 | $0.79 | $19.75K | 142,380 |
| Mark Voll Chief Financial Officer | Apr 3, 2026 | Award | +80,000 | – | – | 117,380 |
| Mark Voll Chief Financial Officer | Mar 25, 2026 | Award | +12,380 | – | – | 37,380 |
| Laurence Marton Director | Mar 20, 2026 | Buy | +9,720 | – | – | 9,720 |
| Mark Voll Chief Financial Officer | Mar 20, 2026 | Buy | +97,200 | – | – | 97,200 |
| Shaun Bagai Chief Executive Officer, Director | Mar 20, 2026 | Buy | +24,300 | – | – | 313,357 |
| Ramtin Agah Chief Medical Officer, Director | Jan 21, 2026 | Buy | +10,000 | $1.00 | $10.00K | 798,460 |
| Ramtin Agah Chief Medical Officer, Director | Dec 31, 2025 | Buy | +9,795 | $0.86 | $8.42K | 788,460 |
| Ramtin Agah Chief Medical Officer, Director | Dec 30, 2025 | Buy | +205 | $0.83 | $170 | 778,665 |
| Shaun Bagai Chief Executive Officer, Director | Dec 18, 2025 | Buy | +5,000 | $0.90 | $4.50K | 340,040 |
| Shaun Bagai Chief Executive Officer, Director | Dec 17, 2025 | Buy | +5,000 | $0.85 | $4.25K | 335,040 |
| Ramtin Agah Chief Medical Officer, Director | Dec 16, 2025 | Buy | +12,000 | $0.85 | $10.20K | 778,460 |
| Ramtin Agah Chief Medical Officer, Director | Dec 5, 2025 | Buy | +10,000 | $0.96 | $9.60K | 766,460 |
| Ramtin Agah Chief Medical Officer, Director | Nov 24, 2025 | Buy | +12,000 | $0.80 | $9.60K | 756,460 |
| Ramtin Agah Chief Medical Officer, Director | Nov 21, 2025 | Buy | +10,000 | $0.80 | $8.00K | 744,460 |
| Shaun Bagai Chief Executive Officer, Director | Aug 25, 2025 | Buy | +5,000 | $0.91 | $4.55K | 330,040 |
| Shaun Bagai Chief Executive Officer, Director | Aug 22, 2025 | Buy | +5,000 | $0.95 | $4.75K | 325,040 |
| Ramtin Agah Chief Medical Officer, Director | Jun 5, 2025 | Buy | +21,000 | $1.40 | $29.40K | 734,460 |
| Laurence Marton Director | May 2, 2025 | Option exercise | +20,480 | $0.15 | $3.07K | 66,164 |
| Ramtin Agah Chief Medical Officer, Director | Apr 22, 2025 | Gift | −400,000 | – | – | 713,460 |
| Ramtin Agah Chief Medical Officer, Director | Apr 15, 2025 | Buy | +15,000 | $0.90 | $13.50K | 1,113,460 |
| Shaun Bagai Chief Executive Officer, Director | Apr 15, 2025 | Buy | +7,500 | $0.91 | $6.83K | 320,040 |
| Ramtin Agah Chief Medical Officer, Director | Apr 11, 2025 | Buy | +20,000 | $0.80 | $16.00K | 1,098,460 |
| Ron Kocak VP Controller and PAO | Apr 10, 2025 | Buy | +6,500 | $0.79 | $5.14K | 12,595 |
| Shaun Bagai Chief Executive Officer, Director | Apr 9, 2025 | Buy | +10,000 | $0.83 | $8.30K | 312,540 |
| Ron Kocak VP Controller and PAO | Apr 9, 2025 | Buy | +6,000 | $0.80 | $4.80K | 6,095 |
| Ramtin Agah Chief Medical Officer, Director | Apr 9, 2025 | Buy | +30,000 | $0.81 | $24.30K | 1,078,460 |
| Ron Kocak VP Controller and PAO | Apr 8, 2025 | Buy | +95 | $0.80 | $76 | 95 |
| Laurence Marton Director | Apr 8, 2025 | Buy | +12,050 | $0.85 | $10.24K | 45,684 |
| Ramtin Agah Chief Medical Officer, Director | Apr 8, 2025 | Buy | +26,000 | $0.84 | $21.84K | 1,048,460 |
| Shaun Bagai Chief Executive Officer, Director | Apr 7, 2025 | Buy | +10,000 | $0.83 | $8.30K | 302,540 |
| Robert J. Spiegel Director | Jan 26, 2024 | Buy | +40,983 | – | – | 40,983 |
| Ramtin Agah Chief Medical Officer, Director | Jan 26, 2024 | Buy | +40,983 | – | – | 47,460 |
| Laurence Marton Director | Jan 26, 2024 | Buy | +8,196 | – | – | 33,634 |
| K. Angela Macfarlane Director | Jan 26, 2024 | Buy | +40,983 | – | – | 40,983 |
| Shaun Bagai Chief Executive Officer, Director | Jan 26, 2024 | Buy | +40,983 | – | – | 292,540 |
| Angela Nelms Chief Operating Officer | Oct 3, 2023 | Buy | +300 | $1.05 | $315 | 300 |
| Angela Nelms Chief Operating Officer | Oct 3, 2023 | Buy | +800 | $1.05 | $840 | 1,100 |
| Laurence Marton Director | Nov 3, 2022 | Option exercise | +25,438 | $1.70 | $43.24K | 25,438 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Jun 7, 2022 | Buy | +5,182 | $1.93 | $10.00K | 6,477 |
| Shaun Bagai Chief Executive Officer, Director | May 19, 2022 | Buy | +5,500 | $2.05 | $11.27K | 251,557 |
| Una S. Ryan Director | Apr 22, 2022 | Other | +26,838 | $0.93 | $24.96K | 80,959 |
| Una S. Ryan Director | Apr 22, 2022 | Other | +16,206 | $1.62 | $26.25K | 97,165 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Mar 16, 2022 | Gift | +975,000 | – | – | 975,000 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Mar 16, 2022 | Gift | −975,000 | – | – | 1,295 |
| Una S. Ryan Director | Mar 3, 2022 | Other | +6,332 | $3.95 | $25.01K | 54,121 |
| Una S. Ryan Director | Mar 3, 2022 | Other | +47,789 | $4.19 | $200.24K | 47,789 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Aug 30, 2021 | Conversion | +1,295 | – | – | 976,295 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.